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ABSTRACT
BACKGROUND: Despite a clear association seen in congenitally infected 
children, the effect of postnatal cytomegalovirus (CMV) infection during 
early childhood on cognitive development has not yet been determined.
METHODS: CMV infection status was obtained based on serological 
measurements when children were 7 years old. Using population-based 
longitudinal data, we employed multivariate Poisson regression with a 
robust variance estimator to characterize the relationship between 
childhood CMV infection and adverse neurocognitive outcomes in children. 
Suboptimal neurocognitive outcomes were compared between CMV-positive 
and CMV-negative children using various cognitive assessments from 8 to 
15 years of age. Children were evaluated on the cognitive domains of 
language, reading, memory, and general intelligence; with a suboptimal 
score being greater than 2 standard deviations lower than the mean score. 
Approximate Bayes factor (ABF) analysis was used to determine the level 
of evidence for the observed associations.
RESULTS: With adjustment for potential confounders, we observed that 
early childhood CMV infection was associated with suboptimal total 
intelligence quotient (IQ) at 8 years of age (incident rate ratio 
(IRR)=2.50, 95% CI 1.35-4.62, ABF=0.08); however, not with suboptimal 
total IQ at 15 years of age (IRR=0.97, 95% CI 0.43-2.19, ABF=1.68). 
Suboptimal attentional control at 8 years (IRR=1.74, 95% CI 1.13-2.68, 
ABF=0.18) and reading comprehension at 9 years (IRR=1.93, 95% CI 1.12-
3.33, ABF=0.24) were also associated with CMV infection. Approximate 
Bayes factor analysis provided strong evidence for the association 
between CMV infection and total IQ at 8 years and only anecdotal evidence 
for attentional control at 8 years and reading comprehension at 9 years. 
All other cognitive measures assessed were not associated with CMV 
infection.
CONCLUSIONS: In this large-scale prospective cohort, we observed some 
evidence for adverse neurocognitive effects of postnatal CMV infection 
on general intelligence during early childhood, however not with lasting 
effect. If confirmed, these results could support the implementation of 
preventative measures to combat postnatal CMV infection.
Key words: cytomegalovirus infection, child neurodevelopment, ALSPAC
Key Messages
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 Adverse neurological and cognitive effects of congenitally 
acquired CMV infection have been well established; however the 
relationship remains unclear for postnatally acquired infection.
 Among a large population-based longitudinal cohort, we observed 
that early childhood CMV infection is associated with intellectual 
impairment in later childhood based on total IQ, however not with 
lasting effect.
 We did not find strong evidence that early childhood CMV infection 
is associated with the cognitive domains of language, attention, 
reading, or memory in later childhood.
 If the observed associations are confirmed, it could provide 
further support for the implementation of preventative measures 
to combat postnatal CMV infection, particularly within early 
childhood.
INTRODUCTION
Cytomegalovirus (CMV) is the most common congenital and perinatal 
infection worldwide (1). It represents a widespread viral infection, but 
remains largely unrecognised globally (2, 3). CMV may be acquired in 
utero (congenital CMV infection), during the birth process due to 
exposure to infected maternal secretions (sometimes referred to as 
perinatal CMV infection), or after birth (postnatal CMV infection) (4). 
Postnatally acquired CMV infections, most commonly resulting from 
transmission through breast milk, but also through blood transfusions or 
other fluid contact with infected individuals, are significantly more 
prevalent than congenitally acquired infections (1). However, the 
majority of what is known about CMV-associated health outcomes is in 
relation to the congenital form, whose prevalence is approximately 0.6-
0.7% in developed countries, and is estimated to be much higher in 
developing nations (5-9). It is one of the most common causes of 
congenital sensorineural hearing loss and has been associated with a wide 
range of adverse neurodevelopmental outcomes such as vision loss, 
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cerebral palsy, microcephaly, as well as motor, behavioural and cognitive 
deficits (5, 8, 10, 11). It has been estimated that upwards of 60% of 
the human population is infected with CMV by adulthood, with infection 
occurring primarily throughout childhood and adolescence (12). 
Seroepidemiologic studies have shown that CMV antibody prevalence is 
influenced by age, geography, cultural factors, socioeconomic status, 
and child-rearing practices (13). 
The extent of the health-related consequences associated with postnatally 
acquired CMV infection is far from clearly understood for the following 
reasons: (i) the delayed onset of adverse health sequelae makes the 
establishment of causal associations difficult; (ii) as postnatal 
infection is largely asymptomatic, it has received little research 
attention compared to the more severe congenital form; and (iii) while 
screening tests have recently become available in few countries (e.g. 
Canada), it is limited to the congenital form of CMV, leaving 
asymptomatic postnatal infection undetected. In addition, universal 
newborn CMV screening remains a contentious point and is currently not 
implemented in most countries, despite community advocacy and the recent 
consensus report from an international panel of experts (3). As CMV is 
known to be neurotropic, it is of great importance to comprehensively 
investigate the effects of postnatally acquired infection.
Previous studies have suggested that CMV infection during early postnatal 
life could impair complex cognitive skills in later childhood (14, 15). 
For the present investigation, our primary goal was to comprehensively 
investigate the association between postnatal CMV infection and a full 
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spectrum of adverse neurocognitive outcomes, as well as to characterize 
factors strongly associated with postnatal CMV infection for target 
surveillance. We hypothesized that children with postnatally acquired 
CMV infection, when compared to uninfected children, more commonly have 
impaired neurodevelopment and suboptimal cognitive abilities in later 
childhood.
METHODS
DATA COLLECTION AND STUDY POPULATION
Population-based data were obtained from the Avon Longitudinal Study of 
Parents and Children (ALSPAC) cohort (16). ALSPAC is a transgenerational 
prospective birth cohort study of children born in the former county of 
Avon in the Bristol area of the UK during 1990-92. It is one of the most 
detailed studies of its kind in the world, with an immense variety of 
health information arising from questionnaire and clinical data 
collection over two decades. It includes genetic, epigenetic, biological, 
psychological, social and other environmental determinants in relation 
to a similarly diverse range of health, behavioural and developmental 
outcomes. The source data and characteristics of the cohort have been 
described in further detail elsewhere (17, 18). Please note that the 
study website contains details of all the data that is available through 
a fully searchable data dictionary and variable search tool (18). 
A flow diagram of participant recruitment is presented in Figure 1. Among 
the 15 589 children enrolled in ALSPAC, 5007 had serological CMV 
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measurement at 7 years and were included in the study population. We 
further excluded children with severe medically-diagnosed neurological 
conditions (e.g. epilepsy, cerebral palsy) and those who were not 
enrolled in school at either 6 years or 9 years of age, which resulted 
in 4988 children in the analysis. These criteria were considered as they 
may have had a large and undue influence on children’s cognitive 
outcomes. The population that had CMV serological data are comparable 
with the overall ALSPAC population in terms of children’s gender 
distribution and method of delivery, but different in other aspects 
(Supplementary Table 1), with higher education levels and longer 
breastfeeding duration among other factors.
(Figure 1 here)
EARLY CHILDHOOD CMV INFECTION
The earliest CMV serological data available from ALSPAC with sufficient 
sample size for statistical analysis was at 7 years of age. Infection 
was measured with three associated variables of CMV IgG antibody titers: 
a raw optical density, a ratio-to-standard, and a normalised z-score of 
that ratio-to-standard. Methods used for IgG antibody measurement were 
based on standard enzyme-linked immunosorbent assay (ELISA) techniques 
which were performed previously (19, 20). CMV IgG antibody titers showed 
a bimodal frequency distribution, thus we used finite mixture modelling 
methods that were previously described to determine a cut-off threshold 
value for CMV positivity (21). For purposes of this study, the CMV ratio-
to-standard optical density measurement was used to characterize 
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infection as it had the most distinct bimodal distribution for threshold 
determination.
NEUROCOGNITIVE OUTCOMES
Neurocognitive impairment, the primary endpoint we aimed to measure, is 
clinically defined as a reduction in cognitive functioning in one or more 
cognitive domains, including memory, attention, learning, language, 
perception, and social cognition (22). A variety of neurocognitive 
measures were available from the ALSPAC cohort, and were chosen based on 
demonstrated ability to characterise different dimensions of cognitive 
capacity. We chose to evaluate neurodevelopment based on the cognitive 
domains of intelligence, language, reading, memory, and attention using 
the Wechsler Intelligence Scale for Children (WISC), the Wechsler 
Objective Language Dimensions (WOLD), the Neale Analysis of Reading 
Ability (NARA), the Counting Span Task, and the Test of Everyday 
Attention for Children (TEA-Ch), respectively. All cognitive assessments 
were administered by experienced and trained psychologists (16).
The WISC-III was used to characterise children’s intellectual ability at 
8 years as it is the most widely used individual intelligence test 
worldwide and is well documented in its ability to assess different 
aspects of intelligence for children between the ages of 6 to 16 (23-
25). A subset of the ALSPAC cohort (n=7488) attended the focus clinic at 
8 years and completed the intelligence assessment using a short form of 
the WISC-III test. The assessment consisted of subtests designed 
specifically for measurement of verbal intelligence quotient (IQ), 
performance IQ, and total IQ, which were calculated from each of the 
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subtests’ total age-scaled scores. An additional intelligence 
measurement was taken at 15 years (n=5,509) using the Weschler 
Abbreviated Scale for Intelligence (WASI). This assessment consisted of 
a measurement for vocabulary, matrix reasoning, and total IQ. 
The language dimensions of listening comprehension and oral expression 
were measured using  WOLD subtests at the focus clinic at 8 years of age 
(n=7488) (26). WOLD consists of individually administered tests designed 
for children aged 6 to 16 years. 
TEA-Ch was used to measure different aspects of attention at 8 years and 
11 years, including: selective attention, the ability to divide attention 
between two tasks, and attentional control (27). TEA-Ch has been 
documented as a valuable tool in assessing specific attentional 
operations and is specifically useful in characterising attentional 
disorders in children between the ages of 6 and 16 (28). The testing was 
performed at ALSPAC focus clinics at 8 years of age (n=7488) and 11 years 
of age (n=7159). 
Reading accuracy and comprehension were measured at 9 years using the 
NARA-II, which is a reading assessment based on a series of short 
narratives suitable for children between the ages of 6 and 12 (29). 
Assessment was administered at the ALSPAC focus clinic at 9 years of age 
(n=7725). Words per minute, accuracy and comprehension standardised 
scores were calculated. Additionally, a classification of developmental 
dyslexia was provided by ALSPAC using a clinical definition of the 
disorder.
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Lastly, working memory was tested using the Counting Span Task at 10 
years of age (n=7563). Working memory was an important cognitive 
component to assess as it has been implicated as a crucial ability in 
reading and arithmetic. Working memory tasks require the simultaneous 
processing and storage of information (30). The Counting Span Task is a 
widely accepted measure of working memory capacity with documented 
reliability and validity (31). 
For each of the composite scores measuring different aspects of cognitive 
functioning described above, threshold values were chosen in order to 
divide subjects into categories of ‘suboptimal’ and ‘normal’ 
neurocognition. A suboptimal threshold value of more than 2 standard 
deviations (SDs) below the mean score was used for each measurement type 
(in cases where a high score indicated suboptimal, a threshold value of 
more than 2 SDs above the median score was used). 
Ethical approval for the ALSPAC study was obtained from the ALSPAC Ethics 
and Law Committee and the Local Research Ethics Committees. Consent for 
biological samples has been collected in accordance with the Human Tissue 
Act (2004). Informed consent for the use of data collected via 
questionnaires and clinics was obtained from participants following the 
recommendations of the ALSPAC Ethics and Law Committee at the time.  In 
addition, this project was approved by the Research Ethics Board at Mount 
Sinai Hospital. 
CONFOUNDERS
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Potential confounders known to influence cognitive development were 
selected a priori for inclusion in the regression model, including the 
child’s sex (32), ethnicity (33), gestational age (34), duration of 
breastfeeding (35), and the quality of home environment (36), as well as 
the mother’s use of potential harmful substances (e.g. tobacco, alcohol, 
drugs) during pregnancy (37), education levels (as a measure of 
socioeconomic status) (38), and psychological condition (39). We used an 
adaptation of the Home Observation Measurement of the Environment (HOME) 
scoring measure to evaluate aspects of the quantity and quality of 
social, emotional, and cognitive support made available to the child in 
their home environment (40). For greater accuracy of this score, we took 
the average of two measurements which were collected when children were 
6 months and 18 months of age. The mother’s psychological condition after 
giving birth was assessed when the child was 8 months old using the 
Edinburgh Postnatal Depression Scale (EPDS) (41). Lastly, mothers’ use 
of illicit drugs and cigarettes during pregnancy were considered as 
binary (ever/never), and levels of alcohol use during pregnancy were 
considered (none/moderate/heavy) by combining data from multiple 
collection time points and taking the average.
STATISTICAL ANALYSIS
For purposes of target surveillance and prevention, we applied a 
multivariate Poisson regression with a robust variance estimator to 
determine factors strongly associated with CMV postnatal infection 
(measured at 7 years). Exposures investigated included: method of 
delivery, pregnancy size (i.e., singleton vs twin), infant school 
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attendance, biological sex, gestational age, birthweight, HOME score, 
breastfeeding duration, mother’s education, ethnicity, age at delivery, 
EPDS, vitamin supplementation during pregnancy, and use of harmful 
substances (tobacco, alcohol, drugs) during pregnancy. In order to assess 
how factors influence performance on neurocognitive measures 
independently of CMV infection and to evaluate the potential for strong 
confounding, we also conducted a secondary analysis among CMV-negative 
children where we examined the associations between potential confounders 
and  neurocognitive outcomes of interest. 
We employed multivariate Poisson regression with a robust variance 
estimator to estimate the incidence rate ratio (IRR), and 95% confidence 
interval (CI) to evaluate the association between CMV seropositivity at 
7 years of age and suboptimal cognitive outcomes. The biological sex of 
the child was then assessed as a potential effect modifier by stratified 
analysis. 
Imputation was used to limit missingness of the covariates in the 
regression models. When missing, mother’s education, breastfeeding 
duration and average HOME score were imputed to the median value of each 
variable for those with CMV serological data (i.e., the analysis 
subpopulation). Statistical analysis was performed using Stata 
statistical and data analysis software version 15.0 (42).
APPROXIMATE BAYES FACTOR ANALYSIS
In order to mitigate the potential issue of multiple comparisons, we 
estimated the approximate Bayes factor (ABF) based on methods previously 
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described to assess the noteworthiness of observed associations (43-45). 
An ABF can be interpreted as a measure of the strength of evidence in 
favour of the alternative hypothesis compared to the null and does not 
depend on the number of comparisons. An ABF of less than 0.1 or greater 
than 10 is considered strong evidence for the alternative hypothesis; 
0.1-0.33 or 3-10 is moderate evidence; 0.33-1 or 1-3 is anecdotal 
evidence; and 1 is no evidence (46).
RESULTS
Study Population and Factors Associated with CMV Infection
Demographic data on the study population is summarized in Table 1. There 
were 4988 participants that had s rological CMV data at 7 years of age 
and met inclusion criteria for the analysis. Overall, 51.8% were boys, 
98.3% were from mothers with European ancestry, and mean gestational age 
was 39.4 weeks. Of these participants, 864 (17.3%) were classified as 
CMV ‘positive’ (CMV+; infected) and 4124 (82.7%) were classified as CMV 
‘negative’ (CMV-; uninfected) based on the threshold value computed using 
IgG antibody titers. Children in the CMV+ and CMV- groups were comparable 
on most child and maternal parameters. Table 1 also summarizes the 
mutually adjusted factors associated with CMV infection. As reported in 
previous studies (47), longer breastfeeding duration was shown to be 
associated with CMV infection.  Mothers of non-European ancestry were 
found to have a positive association with children’s CMV infection when 
compared to mothers with European ancestry (IRR=2.34, 95% CI 1.52-3.59). 
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Furthermore, twin pregnancy was found to have an inverse association with 
CMV infection (IRR=0.40, 95% CI 0.17-0.95). 
(Table 1 here)
Factors Associated with Neurocognitive Outcomes
Table 2 summarizes the associations between potential confounding factors 
and the primary outcome of interest, WISC total IQ at 8 years, in the 
absence of CMV infection. There was strong evidence for associations 
between HOME score and suboptimal WISC total IQ at 8 years (IRR=0.64, 
95% CI 0.53-0.77, ABF<0.01). The associations between potential 
confounders and other cognitive outcomes are summarized in Supplementary 
Tables 2a-d. In brief, we observed associations between breastfeeding 
duration (6+ months), alcohol use during pregnancy (>7 units per week) 
and  TEA-Ch attentional control at 8 years (IRR=0.40, 95% CI 0.21-0.75, 
ABF=0.09; IRR=2.34, 95% CI 1.31-4.18, ABF=0.09, respectively), and 
child’s sex with NARA reading comprehension at 9 years (IRR=0.31, 95% CI 
0.15-0.63, ABF=0.05).
(Table 2 here)
Effects of CMV Infection on Neurocognition
Table 3 summarizes the results of the association of CMV with children’s 
neurodevelopment. After adjustment for potential confounders, CMV 
infection was associated with suboptimal WISC total IQ at 8 years 
(IRR=2.50, 95% CI 1.35-4.62, ABF=0.08) but not with WASI total IQ at 15 
years (IRR=0.97, 95% CI 0.43-2.19, ABF=1.68). CMV infection was also 
associated with suboptimal attentional control using the TEA-Ch at 8 
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years (IRR=1.74, 95% CI=1.13-2.68, ABF=0.18), but not at 11 years 
(IRR=1.07, 95% CI 0.65-1.77, ABF=2.33). Based on the NARA at 9 years, 
CMV infection indicated a higher risk for suboptimal reading 
comprehension (IRR=1.93, 95% CI 1.12-3.33, ABF=0.24). All other measures 
of intelligence, attention and reading were not associated with CMV 
infection. Similarly, measures of suboptimal language dimensions and 
working memory were not found to be associated with CMV infection. ABF 
analysis suggested that there was strong evidence for the association 
between CMV infection and lower WISC total IQ at 8 years, but only 
moderate evidence for suboptimal TEA-Ch attentional control at 8 years 
and NARA reading comprehension at 9 years.
(Table 3 here)
We further assessed whether the associations differed by the sex of the 
child. Results of the sex-stratified analysis and we observed no 
differences between boys and girls on any cognitive assessments 
(Supplementary Table 3). 
DISCUSSION
To our knowledge, this is the largest and longest prospective 
longitudinal analysis investigating neurocognitive outcomes in children 
infected postnatally with CMV. Our analysis supported previous 
associations reported regarding longer breastfeeding duration and 
ethnicity being major influential exposures for postnatal CMV infection 
(48). Our results provide some evidence for adverse neurocognitive 
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effects of postnatal CMV infection on total IQ during early childhood, 
but this effect may be short-lived as subsequent measurement of total IQ 
in later adolescence yielded no association. Overall, postnatal CMV 
infection did not appear to influence cognitive performance on the 
majority of other measures that were assessed. 
It is widely recognized that symptomatic congenital CMV infection has 
widespread neurological and developmental consequences (6), however few 
have studied either asymptomatic congenital CMV infection or postnatal 
infection. In particular, previous studies focusing on asymptomatic 
congenital CMV and neurodevelopment have found inconsistent associations 
(49-53), and postnatal CMV infection and neurodevelopment has only been 
studied in higher-risk subpopulations, such as preterm infants to date 
(14, 54-56). Overall, results have been inconclusive and highlight the 
gap in current knowledge related to CMV infection and cognitive 
impairment.
There are various proposed mechanisms as to how CMV infection may impair 
neurological and cognitive abilities. A recent study of postnatal CMV 
infection in preterm infants using sophisticated MRI analyses found that 
subtle neural alterations (e.g., regional differences in functional 
activation or disturbances within the neural networks) may explain the 
neurological sequelae in infected individuals (14, 47). It has also been 
hypothesized that the observed association between CMV and intelligence 
could be mediated by leukocytes. Higher CMV IgG titres have been 
associated with lower leukocyte telomerase activity and shorter leukocyte 
telomere length in healthy adults, while longer leukocyte telomeres were 
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associated with superior cognitive performance in a large meta-analysis 
(57-59). Finally, CMV infection has also been shown to modulate 
inflammatory and anti-inflammatory circulating biomarkers (e.g., 
cytokines, receptor antagonists, immune cells, and metabolic markers) 
and in turn, these neuroimmune factors may increase neurodegeneration 
and affect cognitive performance (55).
It has been previously concluded that sex modulates neuroimmune factors, 
cognitive performance, and the relationship between the two domains (50, 
51, 55). Therefore, we sought to understand how biological sex impacted 
the associations between CMV infection and neurocognitive measures. The 
sex-stratified analysis suggested there is no differential effect of 
postnatal CMV infection on cognition between boys and girls.
It should be noted that cognitive domains are not independent of one 
another as domains of cognitive functioning are hierarchical in nature, 
ranging from basic sensory and perceptual processes to higher executive 
functioning and cognitive control. Therefore, scores on different 
measures may be inter-related based on the same underlying mechanisms of 
neurocognitive development. For example, language deficits may be 
associated with deficits of executive functioning and processing speed 
(60). Further, interrelationships between reading and intelligence are 
widely recognized, especially in children (61, 62). For example, we 
observed correlation between WISC at 8 years of age and NARA reading 
comprehension at 9 years of age (Pearson correlation= 0.64, p<0.05), 
which is also reflected in their associations with CMV infection.  The 
specific tests of different domains may provide information on each 
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domain, while the global executive functioning is the general 
representation that involved each domain (60). 
Although we observed an association between CMV infection and 
neurocognitive impairment using WISC total IQ at 8 years of age, we did 
not observe the same impairment in WASI total IQ at 15 years of age. 
There are several possible reasons that could explain these differences 
over time: (i) children scoring sub-optimally at the 8-year measurement 
were less likely to continue to participate in measurement at the later 
time point than children who scored within normal range (44% vs. 63% 
retention, respectively); (ii) cognitive impairment due to CMV infection 
may not be long-lasting (53, 63). In other words, CMV infection may cause 
a deficit in cognitive domains during early childhood; however it is 
possible that infected individuals may compensate cognitively by 
adolescence; and/or, (iii) CMV seropositivity status at 7 years captures 
all children who contracted CMV in utero up to age 7. Given the extended 
lag time needed between CMV infection and adverse neurodevelopment 
sequelae, the cognitive impairment observed at 8 years is likely due to 
CMV infection during the toddler time period (critical for brain 
development), whereas the effect of later CMV infection is likely to be 
reflected in cognitive measurements at 11 or 15 years old. Therefore, 
the alternative hypothesis of this observation is that only postnatal 
infection within infancy or the toddler period, when the brain tissue is 
under active development, would have an effect on cognitive impairment 
(as manifested at 8 years), and possibly not CMV infection acquired later 
on at school age. However, given the timing of the CMV measurement, we 
are not able to tease out the susceptibility time period in this analysis, 
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which is a limitation.  One related limitation is that we were also not 
able to distinguish congenital CMV infection from early childhood CMV 
infection.  However, congenital CMV infection is rare at merely 0.6-
0.7%, compared to up to 20% prevalence of CMV infection in childhood. 
Thus, while we do not expect congenital infection to be driving the 
association we observed, we cannot preclude this possibility. It is 
important for our results to be confirmed in a future study where 
differentiation between congenital and postnatal CMV is possible. For 
future investigations, it would be best to have multiple earlier 
serological measurements of CMV antibodies within the first years of life 
in order to identify the timing of infection and the susceptible time 
window related to potential adverse sequelae later on.  
Another limitation of using data from this specific UK-based cohort was 
the ethnic homogeneity of the study population. The total proportion of 
mothers with European ancestry recruited eclipsed that of non-Caucasian 
races (~97% Caucasian vs ~3% all other ethnicities combined), making a 
detailed analysis on ethnic subgroups impossible. Lastly, it is possible 
that children’s overall health status is related to viral antibody 
levels, and it may influence a child’s performance on cognitive tests. 
We did not have data on the overall health status of children and were 
therefore unable to characterise this relationship or account for it in 
our modelling. However, it is likely that overall health status would 
mediate, rather than confound, the relationship between CMV infection 
and suboptimal neurocognitive outcomes. Therefore it is unlikely to  
result in a biased association when unaccounted for.
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The key strengths of this study are the size of the study population, 
the length of follow-up and the extent of cognitive assessments that were 
conducted prospectively. Previous studies examining postnatal CMV 
infection have primarily focused on much narrower study populations 
arising from single-centre recruitment. This investigation represents 
the largest analysis conducted for postnatal CMV infection and children’s 
cognitive outcomes for multiple constructs at multiple time points.
In conclusion, based on a longitudinal study assessing neurocognitive 
sequelae of children infected postnatally with CMV, we observed a 
potential increased risk of suboptimal general intelligence associated 
with infection, although the effect may not be long-lasting. However, 
the majority of our findings support the null hypothesis that postnatal 
CMV infection is not associated with adverse neurocognition in later 
childhood. Nonetheless, our study provides a foundation and motive for 
further research into the largely understudied relationship between 
postnatal CMV infection and adverse neurocognitive outcomes, with 
specific focus on timing of susceptibility. In future investigations, 
measurements of IgG avidity as well as other antibody types (e.g., IgM) 
in addition to IgG could help to differentiate active, reactivated, and 
past CMV infections and shed further insights on CMV sequelae related to 
the susceptible time window. As CMV is the most wide-ranging and 
prevalent perinatal infection, and its health consequences are largely 
unknown, knowledge of its role in neurocognitive development could be 
beneficial to population health. Knowledge of children’s heightened risk 
for adverse cognitive outcomes associated with postnatal CMV infection 
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is important when evaluating whether early interventions to mitigate 
long-term effects of CMV infection are warranted.
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Figure 1. Flow diagram depicting study participant recruitment and exclusions 
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Table 1. Baseline Characteristics of the overall study sample by CMV infection status
*All factors were investigated for their association with CMV infection status at 7 years in a single modified Poisson model, therefore 
mutually adjusting for all other factors under investigation.
aThe number of observations included in the study sample was dependent on the availability of serological CMV data.
bInfant school/preschool attendance was assessed as either full-time or part-time attendance when the child was 65 months (5 years, 5 
months) of age. 
cHome Observation for Measurement of the Environment (HOME) score was measured when the child was 6 months and 18 months 
of age, and is a score of 0 to 12 based on the quality of the home environment for child development including cognitive stimulation 
and emotional support measures, with a higher score indicating greater environment quality.
Overall Study Sample 
(n=4988)a
CMV Positive (n=864) CMV Negative 
(n=4124)
Incidence-Rate Ratio 
of CMV infection* P value
n (%) n (%) n (%) IRR (95% CI)
Child Characteristics
Sex
     Male 2582 (51.8) 447 (51.9) 2135 (51.8) 1.00 (Reference) -
     Female 2401 (48.2) 415 (48.1) 1986 (48.2) 0.93 (0.78,1.12) 0.44
Gestational age, weeks, 
mean
39.4 (SD=1.8) 39.4 (SD=1.8) 39.5 (SD=1.8) 0.97 (0.91,1.03) 0.34
Birthweight, grams, mean 3436.1 (SD=545.2) 3429.1 (SD=542.9) 3437.6 (SD=545.8) 1.00 (1.00,1.00) 0.57
Pregnancy size
     Singleton 4866 (97.7) 848 (98.4) 4018 (97.5) 1.00 (Reference) -
     Twin 117 (2.3) 14 (1.6) 103 (2.5) 0.40 (0.17,0.95) 0.04
Breastfeeding duration
     Never 845 (19.7) 87 (11.7) 758 (21.4) 1.00 (Reference) -
     <3 months 934 (21.8) 120 (16.2) 814 (22.9) 1.15 (0.81,1.63) 0.45
     3-5 months 777 (18.1) 146 (19.7) 631 (17.8) 1.61 (1.14,2.27) <0.01
     6+ months 1734 (40.4) 388 (52.4) 1346 (37.9) 1.79 (1.30,2.46) <0.01
Attended infant 
school/preschoolb
3851 (85.1) 661 (84.9) 3190 (85.2) 1.04 (0.75,1.45) 0.82
HOME score, meanc 9.2 (SD=1.7) 9.4 (SD=1.7) 9.2 (SD=1.6) 1.05 (0.99,1.12) 0.11
Maternal 
Characteristics
Maternal age at delivery, 
years, mean 
29.2 (SD=4.6) 29.6 (SD=4.7) 29.1 (SD=4.6) 0.99 (0.97,1.01) 0.28
Method of delivery
     Vaginal, spontaneous 1688 (61.1) 312 (63.3) 1376 (60.7) 1.00 (Reference) -
     Vaginal, assisted 551 (20.0) 96 (19.5) 455 (20.1) 0.94 (0.75,1.18) 0.60
     Caesarean 522 (18.9) 85 (17.2) 437 (19.3) 0.85 (0.66,1.10) 0.22
Ethnicity
     European 4433 (98.3) 740 (96.4) 3693 (98.7) 1.00 (Reference) -
     Other ethnic group 75 (1.7) 28 (3.6) 47 (1.3) 2.34 (1.52,3.59) <0.01
Substance use during 
pregnancyd
     Cigarette use 928 (19.8) 143 (17.9) 785 (20.3) 1.06 (0.83,1.36) 0.64
     Alcohol use  
          <1 unit per week 2599 (55.6) 426 (53.3) 2173 (56.1) 1.00 (Reference) -
          1-6 units per week 1534 (32.8) 271 (33.9) 1263 (32.6) 1.14 (0.94,1.39) 0.18
          ≥7 units per week 539 (11.5) 102 (12.8) 437 (11.3) 1.19 (0.91,1.56) 0.21
     Illicit drug use 124 (2.7) 31 (3.9) 93 (2.4) 1.41 (0.88,2.25) 0.15
Vitamin supplementation 
during pregnancye
983 (21.2) 184 (23.2) 799 (20.8) 0.97 (0.78,1.21) 0.80
Mother’s Education 
Levelf
     None/CSE 577 (12.8) 92 (11.9) 485 (12.9) 1.00 (Reference) -
     Vocational 382 (8.5) 51 (6.6) 331 (8.8) 0.78 (0.49,1.23) 0.28
     O-Level 1567 (34.7) 234 (30.2) 1333 (35.6) 0.84 (0.60,1.18) 0.32
     A-Level 1224 (27.1) 220 (28.4) 1004 (26.8) 0.93 (0.66,1.31) 0.68
     Degree 770 (17.0) 177 (22.9) 593 (15.8) 1.11 (0.76,1.61) 0.59
Mother’s EPDS, meang 5.2 (SD=4.5) 5.2 (SD=4.5) 5.2 (SD=4.5) 1.00 (0.98,1.02) 0.66
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dUsers of harmful substances during pregnancy included those who reported any use of cigarettes/tobacco, alcohol, or illicit drugs at 
any point during pregnancy. Illicit drugs included cannabis, amphetamine, barbiturate, crack, cocaine, heroin, methadone, and ecstasy.
eMother’s vitamin supplementation during pregnancy was assessed at both 18 weeks gestation and 32 weeks gestation.
fMother’s education level at 32 weeks gestation was obtained based on a 5-point UK education scale, including: none/CSE level, 
vocational level, O-level, A-level, and University Degree level.
gMother’s Edinburgh Post-natal Depression Score was assessed when the child was 8 months of age on a scale of 0 to 29, with a 
higher score indicating more symptoms of depression.
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Table 2. Associations between confounders and suboptimal total IQ (WISC 8 years) 
(among CMV-negative children)
Potential Confounders Incidence-Rate Ratio of suboptimal 
neurocognitive outcome
P value
IRR (95% CI)
Child Characteristics
Sex
     Male 1.00 (Reference) -
     Female 0.50 (0.23,1.08) 0.08
Gestational age, weeks, mean 1.10 (0.86,1.41) 0.46
Breastfeeding duration
     Never 1.00 (Reference) -
     <3 months 0.30 (0.08,1.12) 0.07
     3-5 months 1.03 (0.41,2.55) 0.96
     6+ months 0.53 (0.18,1.56) 0.25
HOME score, mean 0.64 (0.53,0.77) <0.01
Maternal Characteristics
Substance use during pregnancy
     Cigarette use 1.44 (0.65,3.16) 0.37
     Alcohol use
          <1 unit per week 1.00 (Reference) -
          1-6 units per week 0.45 (0.19,1.10) 0.08
          ≥7 units per week 0.70 (0.20,2.42) 0.57
Mother’s Education Level
     None/CSE 1.00 (Reference) -
     Vocational 1.89 (0.66,5.41) 0.24
     O-Level 0.68 (0.24,1.92) 0.47
     A-Level 0.30 (0.07,1.39) 0.13
     Degree 0.17 (0.02,1.41) 0.10
Mother’s EPDS, mean 0.96 (0.89,1.05) 0.38
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Table 3. Associations between CMV infection status and suboptimal neurocognitive outcomes (with adjustment for 
confounders)
*Each suboptimal neurocognitive outcome was analysed in a separate multivariate modified Poisson regression model, adjusting for 
the child’s sex, ethnicity, gestational age, duration of breastfeeding, HOME score, mother’s education, mother’s postnatal 
psychological condition (using EPDS), and mother’s use of tobacco, alcohol, and illicit drugs during pregnancy.
aIncidence-rate ratio of the suboptimal neurocognitive outcome for those who are CMV positive, compared to those who are CMV 
negative (i.e., CMV negative is the reference group).
bProportion of observations with suboptimal neurocognitive outcome, defined by 2 SDs below (or above, if a high score indicates the 
adverse outcome) the mean score for the entire cohort.
cThe definition of developmental dyslexia was devised by Julie Williams and Alan Emond and is based on the accuracy component of 
the NARA II. The equivalent reading age based on the accuracy score is calculated from the NARA II manual and the difference 
between this and the actual age is calculated. Where the child’s reading age is greater than or equal to 30 months (2.5 years) behind 
the actual age AND the child's WISC Total IQ is greater than or equal to 85 the child is considered developmentally dyslexic.
CMV Positive 
(infected)
(n=864)
CMV Negative 
(control)
(n=4124)
Incidence-Rate Ratio of 
suboptimal 
neurocognitive 
outcomea
P value
Approx. 
Bayes 
factor
Suboptimal Neurocognitive Outcome* n/Nb (%) n/Nb (%) IRR (95% CI)
Wechsler Intelligence Scale for Children 
(WISC), 8 years
     Verbal IQ 9/718 (1.3) 54/3436 (1.6) 1.38 (0.70,2.73) 0.36 1.38
     Performance IQ 11/717 (1.5) 44/3431 (1.3) 1.77 (0.92,3.39) 0.09 0.65
     Total IQ 14/715 (2.0) 41/3423 (1.2) 2.50 (1.35,4.62) <0.01 0.08
     Verbal Comprehension Index 9/713 (1.3) 56/3407 (1.6) 1.10 (0.53,2.29) 0.80 1.76
     Perceptual Organization Index 16/682 (2.3) 60/3226 (1.9) 1.66 (0.93,2.98) 0.09 0.69
     Freedom from Distractibility Index 9/699 (1.3) 66/3342 (2.0) 0.85 (0.41,1.76) 0.66 1.69
Wechsler Objective Language Dimensions 
(WOLD), 8 years
     Comprehension Score 15/715 (2.1) 75/3448 (2.2) 0.94 (0.50,1.78) 0.86 1.96
     Expression Score 19/710 (2.7) 95/3441 (2.8) 1.04 (0.61,1.76) 0.89 2.30
     Expression Score (description, 
     direction, sequencing task)
5/463 (1.1) 26/2293 (1.1) 1.29 (0.49,3.37) 0.61 1.41
Test of Everyday Attention for Children 
(TEA-Ch), 8 years
     Selective Attention Score 32/694 (4.6) 105/3349 (3.1) 1.43 (0.95,2.15) 0.09 0.78
     Dividing Attention Score 18/531 (3.4) 76/2603 (2.9) 1.23 (0.71,2.14) 0.45 1.79
     Attentional Control (same world) 27/699 (3.9) 88/3370 (2.6) 1.74 (1.13,2.68) 0.01 0.18
     Attentional Control (opposite world) 15/697 (2.2) 48/3368 (1.4) 1.65 (0.90,3.02) 0.11 0.75
Neale Analysis of Reading Ability 
(NARA), 9 years
     Words per Minute Score 15/653 (2.3) 88/3094 (2.8) 1.05 (0.59,1.87) 0.88 2.13
     Accuracy Score 20/654 (3.1) 87/3102 (2.8) 1.28 (0.75,2.16) 0.36 1.64
     Comprehension Score 17/654 (2.6) 66/3102 (2.1) 1.93 (1.12,3.33) 0.02 0.24
     Developmental dyslexiac 22/734 (3.0) 72/3456 (2.1) 1.55 (0.92,2.63) 0.10 0.79
Counting Span Task (Working Memory), 
10 years
     Working Memory Global Scored 39/677 (5.8) 151/3120 (4.8) 1.35 (0.93,1.97) 0.12 1.04
     Working Memory Span Score 8/677 (1.2) 47/3120 (1.5) 0.84 (0.40,1.77) 0.65 1.66
Test of Everyday Attention for Children 
(TEA-Ch), 11 years
     Selective Attention Score 17/661 (2.6) 92/3156 (2.9) 1.00 (0.56,1.77) 0.99 2.17
     Dividing Attention Score 6/650 (0.9) 32/3113 (1.0) 1.18 (0.50,2.77) 0.71 1.56
     Attentional Control (same world) 23/646 (3.6) 100/3032 (3.3) 1.07 (0.65,1.77) 0.79 2.33
     Attentional Control (opposite world) 26/645 (4.0) 91/3031 (3.0) 1.55 (0.98,2.43) 0.06 0.55
Wechsler Abbreviated Scale of 
Intelligence (WASI), 15 years
     Vocabulary Score 14/523 (2.7) 63/2438 (2.6) 1.16 (0.60,2.26) 0.66 1.80
     Matrix Reasoning Score 19/523 (3.6) 86/2436 (3.5) 1.21 (0.73,2.02) 0.45 1.90
     Total IQ 7/523 (1.3) 44/2435 (1.8) 0.97 (0.43,2.19) 0.94 1.68
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dSuboptimal working memory global score was defined by ≤5th percentile, as 2 SDs below the mean yielded a threshold that was too 
stringent (i.e., there were <5 observations in any cell for comparison in the overall sample).
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